7-24749655-CTTTT-CTTTTT
Position:
Variant summary
Our verdict is Uncertain significance. Variant got 3 ACMG points: 8P and 5B. PVS1BP6BS2
The NM_001127453.2(GSDME):c.119dupA(p.Lys41fs) variant causes a frameshift change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.00075 in 1,613,944 control chromosomes in the GnomAD database, including 16 homozygotes. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.00083 ( 2 hom., cov: 32)
Exomes 𝑓: 0.00074 ( 14 hom. )
Consequence
GSDME
NM_001127453.2 frameshift
NM_001127453.2 frameshift
Scores
Not classified
Clinical Significance
Conservation
PhyloP100: 0.526
Genes affected
GSDME (HGNC:2810): (gasdermin E) Hearing impairment is a heterogeneous condition with over 40 loci described. The protein encoded by this gene is expressed in fetal cochlea, however, its function is not known. Nonsyndromic hearing impairment is associated with a mutation in this gene. Three transcript variants encoding two different isoforms have been found for this gene. [provided by RefSeq, Jul 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Uncertain_significance. Variant got 3 ACMG points.
PVS1
Loss of function variant, product undergoes nonsense mediated mRNA decay. LoF is a known mechanism of disease.
BP6
Variant 7-24749655-C-CT is Benign according to our data. Variant chr7-24749655-C-CT is described in ClinVar as [Conflicting_classifications_of_pathogenicity]. Clinvar id is 228555.We mark this variant Likely_benign, oryginal submissions are: {Likely_benign=2, Uncertain_significance=1, Benign=2}.
BS2
High AC in GnomAd4 at 127 AD gene.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GSDME | NM_001127453.2 | c.119dupA | p.Lys41fs | frameshift_variant | 2/10 | ENST00000645220.1 | NP_001120925.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GSDME | ENST00000645220.1 | c.119dupA | p.Lys41fs | frameshift_variant | 2/10 | NM_001127453.2 | ENSP00000494186.1 |
Frequencies
GnomAD3 genomes AF: 0.000835 AC: 127AN: 152160Hom.: 2 Cov.: 32
GnomAD3 genomes
AF:
AC:
127
AN:
152160
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.00152 AC: 381AN: 251436Hom.: 8 AF XY: 0.00130 AC XY: 177AN XY: 135890
GnomAD3 exomes
AF:
AC:
381
AN:
251436
Hom.:
AF XY:
AC XY:
177
AN XY:
135890
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.000742 AC: 1084AN: 1461784Hom.: 14 Cov.: 33 AF XY: 0.000712 AC XY: 518AN XY: 727200
GnomAD4 exome
AF:
AC:
1084
AN:
1461784
Hom.:
Cov.:
33
AF XY:
AC XY:
518
AN XY:
727200
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.000835 AC: 127AN: 152160Hom.: 2 Cov.: 32 AF XY: 0.000646 AC XY: 48AN XY: 74332
GnomAD4 genome
AF:
AC:
127
AN:
152160
Hom.:
Cov.:
32
AF XY:
AC XY:
48
AN XY:
74332
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Bravo
AF:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Conflicting classifications of pathogenicity
Submissions summary: Uncertain:1Benign:5
Revision: criteria provided, conflicting classifications
LINK: link
Submissions by phenotype
not provided Benign:3
Likely benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 06, 2024 | - - |
Benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Jul 01, 2022 | GSDME: BS1, BS2 - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Mar 14, 2022 | - - |
not specified Uncertain:1
Uncertain significance, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Nov 12, 2015 | Variant classified as Uncertain Significance - Favor Benign. The p.Lys41fs varia nt in DFNA5 has not been previously reported in individuals with hearing loss, b ut has been identified in 0.21% (137/66836) of European chromosomes by the Exome Aggregation Consortium (ExAC, http://exac.broadinstitute.org; dbSNP rs758488919 ). This variant is predicted to cause a frameshift, which alters the protein?s a mino acid sequence beginning at position 41 and leads to a premature termination codon 113 amino acids downstream. This alteration is then predicted to lead to a truncated or absent protein. However, only variants resulting in altered splic ing and skipping of exon 8 have been reported to be causative for hearing loss t hrough a gain of function mechanism of disease (Van Laer 2004). The p.Lys41fs va riant is located in exon 2 of DFNA5 and is expected to result in loss of functio n (LoF), which is not a known mechanism of hearing loss in this gene. In fact, a frameshift variant in DFNA5 has been reported in members of an Iranian family, in which the variant did not segregate with the hearing loss (Van Laer 2007). In summary, while the clinical significance of the p.Lys41fs variant is uncertain, its frequency in the general population and the lack of evidence supporting a L oF mechanism for hearing loss in DFNA5 suggests it is more likely to be benign. - |
Nonsyndromic genetic hearing loss Benign:1
Benign, criteria provided, single submitter | clinical testing | INGEBI, INGEBI / CONICET | Jul 15, 2021 | Based on ACMG/AMP guidelines and Hearing Loss Expert Panel specific criteria: The filter allele frequency of c.119dupA in DFNA5 gene is 2.9% (330/10368 with 95%CI) in Ashkenazi Jewish population in gnomad database, exceeding the treshold for autosomal dominant non-syndromic hearing loss stablished by the Hearing Loss Expert Panel group, meeting BA1. Although c.119dup is a frameshift variant (p.Lys41Glufs*113), it was reported that DFNA5-associated hearing loss is caused by a gain-of-function and not haplo-insufficiency (PMID:15173223, 7427029). Therefore PVS1 is not applied. In this report, c.119dupA was a confirmed de novo occurence identified in a sporadic congenital moderate non-syndromic hearing loss patient, meeting PS2. Considering BA1 and PS2, the variant is classifie as Benign. - |
GSDME-related disorder Benign:1
Benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Mar 12, 2020 | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at